The stock of Cryolife Inc (NYSE:CRY) hit a new 52-week high and has $21.65 target or 8.00% above today’s $20.05 share price. The 5 months bullish chart indicates low risk for the $673.85M company. The 1-year high was reported on Nov, 25 by Barchart.com. If the $21.65 price target is reached, the company will be worth $53.91 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 32,395 shares traded hands. Cryolife Inc (NYSE:CRY) has risen 59.97% since April 22, 2016 and is uptrending. It has outperformed by 54.56% the S&P500.
Analysts await Cryolife Inc (NYSE:CRY) to report earnings on February, 20. They expect $0.08 EPS, down 38.46% or $0.05 from last year’s $0.13 per share. CRY’s profit will be $2.69M for 62.66 P/E if the $0.08 EPS becomes a reality. After $0.13 actual EPS reported by Cryolife Inc for the previous quarter, Wall Street now forecasts -38.46% negative EPS growth.
Cryolife Inc (NYSE:CRY) Ratings Coverage
Out of 2 analysts covering Cryolife (NYSE:CRY), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cryolife has been the topic of 2 analyst reports since April 13, 2016 according to StockzIntelligence Inc. The firm has “Buy” rating given on Wednesday, April 13 by Canaccord Genuity. The company was initiated on Wednesday, June 15 by Lake Street.
According to Zacks Investment Research, “CryoLife, Inc. is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular, and orthopaedic surgeries throughout the United States and Canada. The company’s BioGlue surgical adhesive, the company marked in the European Union for use in vascular and pulmonary sealing and repair, is distributed throughout Europe. The company also manufactures CryoLife- O’Brien and CryoLife-Ross stentless porcine heart valves which are distributed within the European Community. (PRESS RELEASE)”
Insitutional Activity: The institutional sentiment decreased to 1.58 in Q2 2016. Its down 0.61, from 2.19 in 2016Q1. The ratio dropped, as 8 funds sold all Cryolife Inc shares owned while 24 reduced positions. 20 funds bought stakes while 50 increased positions. They now own 19.57 million shares or 9.07% more from 17.94 million shares in 2016Q1.
Portolan Cap Mgmt Limited Liability Corp holds 0.94% of its portfolio in Cryolife Inc (NYSE:CRY) for 551,271 shares. Art Llc holds 14,385 shares or 0.01% of its portfolio. Vanguard, a Pennsylvania-based fund reported 1.31 million shares. Rhumbline Advisers holds 0% of its portfolio in Cryolife Inc (NYSE:CRY) for 37,682 shares. The Ontario – Canada-based Retail Bank Of Montreal Can has invested 0% in Cryolife Inc (NYSE:CRY). State Street holds 552,867 shares or 0% of its portfolio. Blackrock reported 3,324 shares or 0% of all its holdings. Magnetar Financial Lc has 10,444 shares for 0% of their US portfolio. Blackrock Grp holds 0% or 22,887 shares in its portfolio. Swiss Bankshares holds 39,900 shares or 0% of its portfolio. Ameriprise Inc holds 0% or 145,061 shares in its portfolio. Geode Lc owns 169,997 shares or 0% of their US portfolio. Wells Fargo Mn holds 0% of its portfolio in Cryolife Inc (NYSE:CRY) for 560,190 shares. Tiaa Cref Inv Management Ltd Com owns 119,052 shares or 0% of their US portfolio. Blackrock Institutional Tru Na holds 0% of its portfolio in Cryolife Inc (NYSE:CRY) for 912,648 shares.
Insider Transactions: Since June 1, 2016, the stock had 0 insider purchases, and 2 sales for $143,600 net activity. 10,000 shares with value of $115,600 were sold by McCall Ronald D on Wednesday, June 1. $28,000 worth of shares were sold by RONALD C ELKINS on Tuesday, July 26.
More important recent Cryolife Inc (NYSE:CRY) news were published by: Prnewswire.com which released: “CryoLife Announces Definitive Agreement to Acquire On-X Life Technologies …” on December 22, 2015, also Prnewswire.com published article titled: “CryoLife Appoints James McDermid as Chief Human Resources Officer”, Prnewswire.com published: “James W. Bullock Joins CryoLife Board of Directors” on October 25, 2016. More interesting news about Cryolife Inc (NYSE:CRY) was released by: Fool.com and their article: “Why Cryolife Inc’s Shares Turned Hot Today” with publication date: July 26, 2016.
CRY Company Profile
CryoLife, Inc. (CryoLife), incorporated on January 19, 1984, is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Firm operates in two divisions: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol). The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.